Evidence map›Paper›PMID 24531078›Full record

ReviewInternational journal of nanomedicine2014

Targeted therapy using nanotechnology: focus on cancer.

Vanna Sanna, Nicolino Pala, Mario Sechi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 485 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review
  9. Therapeutic applications of nanobots and nanocarriers in cancer treatment.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vanna SannaDepartment of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy.
Nicolino PalaDepartment of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy.
Mario SechiDepartment of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy.
University of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets. Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors. BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsAptamers, NucleotideChemistry, PharmaceuticalDelayed-Action PreparationsDocetaxelDrug Delivery SystemsEndothelial CellsHumansLiposomesMolecular Targeted TherapyNanomedicineNanoparticlesNanotechnologyNeoplasmsTaxoidsAntibodies, MonoclonalAntineoplastic AgentsAptamers, NucleotideDelayed-Action PreparationsDocetaxelLiposomesTaxoidsBIND-014cancernanomedicinetargeted nanoparticles

Identifiers

PMID24531078
PMCPMC3896284
OpenAlexW1981412372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.